NNEKA ONUORAH: Open Payments
NPI 1881304905 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$511 in 22 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $474 · 2025 $511
Food & beverage: $511
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $102 |
| ABBVIE INC. | 4 | $79 |
| Lundbeck LLC | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Bausch Health US, LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: INGREZZA, CAPLYTA, REXULTI, VRAYLAR, AUSTEDO XR, TRINTELLIX, WELLBUTRIN.
Industry payments across MD — which companies pay providers there.
